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and longer DAPT (L-DAPT) deﬁned as the per-protocol period of
prolonged DAPT beyond S-DAPT. The primary outcome was the
study-deﬁned major adverse cardiac events (MACE). Random effect
models were used as primary analytic approach with generic in-
verse variance using effect estimates and standard errors extracted
from each RCT’s gender subgroup analysis. Heterogeneity was
assessed with I2 test (with I2 > 75% indicating substantial hetero-
geneity). Analyses were conducted with Cochrane’s Review Man-
ager (RevMan) version 5.3.
RESULTS A total of 13 RCTs with 108.069 patients have been
included in the ﬁnal dataset. Of them, 31,390 (29%) were women
and 76,679 (71%) were men. Mean weighted exposure time to DAPT
was 2.4 months and 5.9 months in the S-DAPT and L-DAPT groups
respectively. Compared with S-DAPT, L-DAPT was associated with a
signiﬁcant reduction in MACE in the overall cohort (Figure. HR:
0.87; 95% CI: 0.82 – 0.92; p < 0.00001; I2 ¼ 18%). However, the
beneﬁt of L-DAPT was accentuated in men (HR: 0.82; 95% CI:
0.76 – 0.90; p < 0.00001) as compared to women (HR: 0.93; 95%
CI: 0.86 – 1.00; p ¼ 0.06) with evidence of statistical interaction
(p for interaction ¼ 0.03).CONCLUSIONS According to the results of the present study-level
metanalysis, the beneﬁts of DAPT appear to be less in women as
compared to men, a ﬁnding that warrants prospective conﬁrmation.
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BACKGROUND Longer DAPT (> 12 months) after drug-eluting stent
(DES) implantation is associated with a lower risk of myocardial
infarction (MI) counterbalanced by a higher risk of major bleeding
events. We sought to simulate the therapeutic risks and beneﬁts of
longer versus short DAPT durations after PCI using evidence from
randomized controlled trials (RCT).
METHODS Using frequentist meta-analytic techniques, we calculated
summary effect estimates for both MI and clinically signiﬁcant
bleeding (CSB) associated with longer (L-DAPT) versus shorter (S-
DAPT) DAPT durations based on results of 10 RCT (n¼32,135). We then
calculated the number needed to treat (NNT) and number needed toharm (NNH) as a function of baseline thrombotic and bleeding risk.
NNT/NNH ratios > 1 were considered as evidence of therapeutic harm
while ratios < 1 were classiﬁed as beneﬁcial.
RESULTS The mean weighted follow-up time among all trials was
19.6 months. Mean weighted exposure time to DAPT was 23.2
months and 8.5 months in L-DAPT and S-DAPT groups respectively.
As compared to S-DAPT, L-DAPT was associated with a lower risk of
MI (odds ratio [OR]: 0.72; 95% CI: 0.62 – 0.83; p < 0.0001).
Conversely, L-DAPT was associated with a higher risk of CSB (OR:
1.59; 95% CI: 1.31 – 1.92; p < 0.00001). The net clinical beneﬁt in the
trade-off between ST and CSB across a range of bleeding and
ischemic risk scenarios is illustrated in Figure 1. With L-DAPT, the
beneﬁt on MI outweighed the risk for bleeding with a ST risk > 6%
and a CSB risk  3%.
CONCLUSIONS Our results suggest that the beneﬁts of longer DAPT
durations may be optimal in patients at high thrombotic or low
bleeding risk, ﬁndings that warrant prospective evaluation.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
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BACKGROUND Randomized data have shown that prasugrel is supe-
rior to clopidogrel in reducing ischemic risk including unplanned
revascularization, albeit with increased bleeding. Greater stent length
is also an independent correlate of adverse events after percutaneous
coronary intervention (PCI). We sought to determine whether
